Please assess the completion status of the following clinical trial:

Trial Title: Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Is male or female, in otherwise good health, 18 to 80 years of age.~2. Has history of chronic migraine (with or without aura) according to the criteria proposed by the Headache Classification Committee of the International Headache Society for at least 3 months prior to enrollment.~3. Has onset of migraine before age 50.~4. Is able to differentiate migraine from any other headache they may experience (e.g., tension-type headache).~5. Is not currently taking a migraine preventive or has been taking preventive for at least 30 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period.~6. If female of childbearing potential, agrees to use, for the duration of the study, a medically acceptable form of contraception as determined by the Investigator.~   1. Complete abstinence from intercourse from 2 weeks prior to administration of study drug throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the study drug; or,~  2. Surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); or,~  3. Sterilization of male partner; or,~  4. Intrauterine device with published data showing lowest expected failure rate is less than 1% per year; or,~  5. Double barrier method (i.e., 2 physical barriers OR 1 physical barrier plus spermicide) for a least 1 month prior to Visit 1 and throughout study; or,~  6. Hormonal contraceptives for at least 3 months prior to Visit 1 and throughout study.~7. Has pain presentation in frontal, temporal, ophthalmic, maxillary, mandibular, facial, or intraoral location.~Exclusion Criteria:~1. Is male or female, in otherwise good health, 18 to 80 years of age.~2. Has history of chronic migraine (with or without aura) according to the criteria proposed by the Headache Classification Committee of the International Headache Society for at least 3 months prior to enrollment.~3. Has onset of migraine before age 50.~4. Is able to differentiate migraine from any other headache they may experience (e.g., tension-type headache).~5. Is not currently taking a migraine preventive or has been taking preventive for at least 30 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period.~6. If female of childbearing potential, agrees to use, for the duration of the study, a medically acceptable form of contraception as determined by the Investigator.~   1. Complete abstinence from intercourse from 2 weeks prior to administration of study drug throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the study drug; or,~  2. Surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); or,~  3. Sterilization of male partner; or,~  4. Intrauterine device with published data showing lowest expected failure rate is less than 1% per year; or,~  5. Double barrier method (i.e., 2 physical barriers OR 1 physical barrier plus spermicide) for a least 1 month prior to Visit 1 and throughout study; or,~  6. Hormonal contraceptives for at least 3 months prior to Visit 1 and throughout study.~7. Has pain presentation in frontal, temporal, ophthalmic, maxillary, mandibular, facial, or intraoral location.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Marcaine (Type: ACTIVE_COMPARATOR): Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the Sphenopalatine Ganglion (SPG)
- Saline (Type: PLACEBO_COMPARATOR): Group B will receive saline placebo delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete